Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized blood thinners could cut stroke risk

NCT ID NCT06269432

Disease control Sponsor: Sichuan Provincial People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a blood test to guide antiplatelet medication can reduce the risk of a second stroke. People who have had a non-cardioembolic ischemic stroke and are already taking aspirin will be assigned to either continue standard aspirin or switch to a different antiplatelet drug based on their test results. The goal is to see if personalized treatment lowers the rate of blood clot-related events within 30 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
aspirin, clopidogrel, ticagrelor
What this could lead to
If successful, this approach could help doctors choose the right antiplatelet drug for each stroke patient, potentially lowering the chance of another stroke or heart attack.
What could go wrong
This is a single trial with 1,224 participants, and results may not apply to all stroke patients. There is also a risk of bleeding with antiplatelet drugs, which the study will monitor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

1,224 people

The number who actually took part.

Started

Jan 2023

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged from 18 to 80 years; 2. Diagnosed with non-cardiogenic ischemic stroke according to WHO criteria, confirmed by cranial CT or MRI to exclude hemorrhagic stroke.; 3. First stroke onset ≥ 1 month and ≤ 3 months; 4. mRS Score \<=2 points; 5. Undergoing antiplatelet therapy with 100mg aspirin daily for at least 8 days; 6. Informed consent signed by the patient or their family member. Exclusion Criteria: 1. History of recurrent stroke. 2. History of gastrointestinal bleeding, intracranial hemorrhage, or other bleeding disorders. 3. Contraindications or intolerance to antiplatelet therapy medications. 4. Severe cardiac, pulmonary, hepatic, or renal insufficiency, or presence of severe comorbid conditions (e.g., end-stage malignant tumors, severe single/multiple organ failure). 5. Poor compliance, inability to cooperate with study requirements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antiplatelet drug are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antiplatelet drug Ischemic stroke

Contacts and locations

Locations

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, 610072, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.